SCHEMBL3895265

SCHEMBL3895265

COc1cc2nccc(Oc3ccc(Cl)cc3C(N)=O)c2cc1OC

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 5/20 0.61
▸ TGFBR1 P36897 5/20 0.61
▸ KDR P35968 10/20 0.58
▸ AURKA O14965 2/20 0.58
▸ MET P08581 2/20 0.58
▸ TEK Q02763 2/20 0.58
▸ AURKB Q96GD4 2/20 0.58
▸ ABL1 P00519 1/20 0.58
▸ LCK P06239 1/20 0.58
▸ LYN P07948 1/20 0.58
▸ PDGFRA P16234 7/20 0.57
▸ PDGFRB P09619 2/20 0.56
▸ CSF1R P07333 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3893720 0.87 SRC (0.60) SRCTGFBR1KDRMETPDGFRA
SCHEMBL28666251 0.85 KDR (0.59) SRCTGFBR1KDRAURKAMET
SCHEMBL3905159 0.84 SRC (0.60) SRCTGFBR1KDRMETPDGFRA
SCHEMBL3896060 0.84 SRC (0.79) SRCTGFBR1KDRMETPDGFRA
Hydrochloric Acid SCHEMBL3904684 0.84 SRC (0.79) SRCTGFBR1KDRMETPDGFRA
SCHEMBL14967409 0.82 SRC (0.63) SRCTGFBR1KDRAURKAMET
SCHEMBL3894133 0.82 SRC (0.71) SRCTGFBR1KDRAURKAMET
SCHEMBL3897489 0.82 KDR (0.67) SRCTGFBR1KDRAURKAMET
SCHEMBL14967481 0.81 SRC (0.58) SRCTGFBR1KDRAURKAMET
SCHEMBL3795531 0.81 PDGFRA (0.61) SRCTGFBR1KDRAURKAMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2009-12-17 — — US disclosed
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2009-12-17 — — US disclosed
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2009-12-17 — — US disclosed
US-7560558-B2 Compound having TGFβ inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2009-07-14 — — US disclosed
US-7560558-B2 Compound having TGFβ inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2009-07-14 — — US disclosed
US-7560558-B2 Compound having TGFβ inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2009-07-14 — — US disclosed
US-20060111375-A1 Compound having tgfß inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-05-25 — — US disclosed
EP-1548008-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2005-06-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111375-A1 Compound having tgfß inhibitory activity and medicinal composition containing the same TGFB1, TGFBR1, TGFBR2 SRC 399/4885TGFBR1 2/4885KDR 233/4885
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME TGFB1, TGFBR1, TGFBR2 SRC 496/4885TGFBR1 2/4885KDR 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback